Qiagen (NYSE:QGEN) Lifted to Outperform at BNP Paribas

BNP Paribas upgraded shares of Qiagen (NYSE:QGEN) from a neutral rating to an outperform rating in a research note published on Friday morning, Briefing.com Automated Import reports.

Several other equities analysts have also issued reports on the company. Deutsche Bank lowered Ontex Group from a buy rating to a hold rating in a report on Wednesday, May 8th. Barclays raised their price objective on from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the stock an equal weight rating in a report on Friday, June 21st. Zacks Investment Research lowered Great Portland Estates from a hold rating to a sell rating in a report on Tuesday, April 16th. UBS Group reissued a sell rating and set a $220.00 price target on shares of Tesla in a report on Friday, March 15th. Finally, Goldman Sachs Group lowered JSR from a neutral rating to a sell rating in a report on Friday, June 21st. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Qiagen currently has a consensus rating of Buy and a consensus price target of $42.00.

Shares of QGEN stock opened at $40.05 on Friday. The business’s 50-day moving average price is $39.63. The stock has a market capitalization of $8.95 billion, a price-to-earnings ratio of 29.89, a price-to-earnings-growth ratio of 2.43 and a beta of 0.84. Qiagen has a 1 year low of $32.33 and a 1 year high of $41.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.52 and a current ratio of 1.69.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.01. The company had revenue of $348.70 million for the quarter, compared to analyst estimates of $351.68 million. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.26 earnings per share. On average, research analysts forecast that Qiagen will post 1.44 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Qiagen by 7.4% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,788 shares of the company’s stock valued at $154,000 after acquiring an additional 260 shares during the period. State of Alaska Department of Revenue lifted its position in shares of Qiagen by 1.6% during the 1st quarter. State of Alaska Department of Revenue now owns 23,913 shares of the company’s stock valued at $972,000 after acquiring an additional 366 shares during the period. Captrust Financial Advisors lifted its position in shares of Qiagen by 165.3% during the 4th quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock valued at $35,000 after acquiring an additional 628 shares during the period. O Shaughnessy Asset Management LLC acquired a new stake in shares of Qiagen during the 1st quarter valued at approximately $30,000. Finally, Strs Ohio lifted its position in shares of Qiagen by 7.0% during the 1st quarter. Strs Ohio now owns 13,081 shares of the company’s stock valued at $532,000 after acquiring an additional 852 shares during the period. 63.20% of the stock is currently owned by institutional investors.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: Bollinger Bands

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.